Stock listing
Dusseldorf:A5I AtriCure, Inc. Aktie
German listing (Dusseldorf) of AtriCure, Inc. · home listing NASDAQ:ATRC
Follow AtriCure, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ATRC
$55.39 USD -0.06 (-0.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ATRC
- Day range
- $54.03 – $56.14 USDNov 20, 2026
- Volume
- 813,080 sharesNov 20, 2026
- Market cap
- $2.82B USDAt the close on Nov 20, 2026 · price × 50.92M shares outstanding
- 52-week range
- $25.36 – $66.02 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $58.43M USDMedian day 850,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ATRC · Home | $55.39 USD | -0.06 (-0.1%) | 813,080 | $54.03 | $56.14 | $54.03 | $55.45 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ATRC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $55.39 | -0.06 | -0.1% | $54.03 | $56.14 | $54.03 | 813,080 | |
| $55.45 | +0.43 | +0.8% | $54.10 | $56.47 | $54.09 | 595,164 | |
| $55.02 | -0.29 | -0.5% | $55.32 | $55.98 | $53.88 | 611,228 | |
| $55.31 | -1.53 | -2.7% | $57.00 | $57.18 | $55.02 | 560,829 | |
| $56.84 | +0.86 | +1.5% | $56.11 | $57.28 | $55.81 | 558,768 | |
| $55.98 | -1.55 | -2.7% | $58.01 | $58.24 | $55.76 | 462,388 | |
| $57.53 | +1.27 | +2.3% | $56.42 | $57.68 | $56.03 | 644,939 | |
| $56.26 | -1.52 | -2.6% | $57.10 | $57.49 | $54.74 | 838,143 | |
| $57.78 | -0.76 | -1.3% | $58.62 | $59.85 | $57.18 | 1,026,136 | |
| $58.54 | -2.74 | -4.5% | $60.00 | $61.11 | $58.35 | 613,513 | |
| $61.28 | -4.25 | -6.5% | $65.00 | $66.00 | $60.58 | 978,420 | |
| $65.53 | +5.12 | +8.5% | $58.06 | $66.02 | $58.00 | 1,335,542 | |
| $60.41 | +0.53 | +0.9% | $59.45 | $61.54 | $59.10 | 1,591,666 | |
| $59.88 | -1.37 | -2.2% | $61.70 | $62.33 | $59.14 | 1,115,758 | |
| $61.25 | -1.23 | -2.0% | $62.41 | $62.41 | $59.70 | 961,279 | |
| $62.48 | +1.06 | +1.7% | $61.71 | $62.86 | $61.69 | 701,155 | |
| $61.42 | -0.09 | -0.1% | $61.37 | $63.00 | $61.06 | 647,548 | |
| $61.51 | +0.43 | +0.7% | $60.86 | $61.78 | $60.08 | 783,123 | |
| $61.08 | +2.11 | +3.6% | $59.35 | $61.17 | $58.85 | 815,923 | |
| $58.97 | -0.33 | -0.6% | $58.94 | $59.56 | $58.53 | 497,089 | |
| $59.30 | +1.63 | +2.8% | $57.76 | $59.54 | $57.76 | 498,177 | |
| $57.67 | 0.00 | 0.0% | $57.73 | $59.29 | $57.13 | 566,328 | |
| $57.67 | +2.14 | +3.9% | $55.64 | $58.20 | $55.64 | 446,379 | |
| $55.53 | -0.54 | -1.0% | $55.75 | $56.58 | $55.16 | 607,217 | |
| $56.07 | -1.71 | -3.0% | $57.98 | $58.31 | $55.90 | 648,300 | |
| $57.78 | +0.48 | +0.8% | $57.83 | $58.44 | $56.27 | 850,900 | |
| $57.30 | +0.43 | +0.8% | $56.13 | $57.89 | $55.84 | 799,300 | |
| $56.87 | -0.41 | -0.7% | $57.60 | $57.98 | $56.39 | 596,100 | |
| $57.28 | +1.47 | +2.6% | $56.29 | $57.35 | $55.67 | 645,600 | |
| $55.81 | +2.97 | +5.6% | $53.14 | $55.89 | $52.44 | 712,500 | |
| $52.84 | -0.47 | -0.9% | $53.07 | $53.46 | $51.63 | 595,600 | |
| $53.31 | -0.37 | -0.7% | $53.35 | $54.88 | $52.98 | 753,500 | |
| $53.68 | -2.69 | -4.8% | $55.97 | $56.58 | $53.43 | 863,700 | |
| $56.37 | +1.23 | +2.2% | $54.14 | $56.60 | $53.86 | 1,095,500 | |
| $55.14 | +1.55 | +2.9% | $52.51 | $55.25 | $52.00 | 1,615,500 | |
| $53.59 | -2.61 | -4.6% | $56.52 | $56.99 | $52.60 | 1,970,900 | |
| $56.20 | -1.85 | -3.2% | $58.01 | $58.60 | $56.15 | 1,111,200 | |
| $58.05 | -0.36 | -0.6% | $58.58 | $59.05 | $56.59 | 876,300 | |
| $58.41 | +0.03 | +0.1% | $57.56 | $58.49 | $56.90 | 1,161,800 | |
| $58.38 | -2.39 | -3.9% | $60.85 | $61.32 | $57.89 | 1,591,200 | |
| $60.77 | +0.81 | +1.4% | $59.63 | $61.70 | $59.13 | 1,304,900 | |
| $59.96 | +1.13 | +1.9% | $58.92 | $61.48 | $58.72 | 1,206,200 | |
| $58.83 | +0.51 | +0.9% | $58.62 | $59.69 | $57.94 | 871,600 | |
| $58.32 | +0.22 | +0.4% | $58.23 | $59.11 | $56.97 | 1,039,700 | |
| $58.10 | -1.02 | -1.7% | $58.51 | $59.88 | $57.98 | 8,670,300 | |
| $59.12 | +1.98 | +3.5% | $57.96 | $59.59 | $57.31 | 1,539,600 | |
| $57.14 | +0.92 | +1.6% | $55.66 | $57.25 | $55.66 | 1,216,900 | |
| $56.22 | +0.43 | +0.8% | $56.00 | $56.78 | $54.65 | 1,432,300 | |
| $55.79 | +1.25 | +2.3% | $54.84 | $56.02 | $54.81 | 1,154,700 | |
| $54.54 | +1.58 | +3.0% | $53.53 | $55.16 | $53.52 | 1,098,900 | |
| $52.96 | -0.07 | -0.1% | $52.31 | $53.66 | $51.86 | 961,900 | |
| $53.03 | -0.70 | -1.3% | $53.16 | $53.71 | $51.97 | 1,659,500 | |
| $53.73 | +2.21 | +4.3% | $54.31 | $55.72 | $51.74 | 1,880,200 | |
| $51.52 | -0.94 | -1.8% | $52.03 | $52.53 | $51.03 | 714,100 | |
| $52.46 | -0.13 | -0.2% | $52.88 | $53.50 | $51.19 | 1,169,100 | |
| $52.59 | +3.67 | +7.5% | $49.76 | $52.69 | $49.54 | 1,262,600 | |
| $48.92 | +0.57 | +1.2% | $48.43 | $49.25 | $47.54 | 717,600 | |
| $48.35 | -0.19 | -0.4% | $48.23 | $48.85 | $46.61 | 529,100 | |
| $48.54 | -0.73 | -1.5% | $49.32 | $49.98 | $48.35 | 390,600 | |
| $49.27 | +1.10 | +2.3% | $48.22 | $49.45 | $47.82 | 766,400 | |
| $48.17 | -0.51 | -1.0% | $48.02 | $48.55 | $47.06 | 859,700 | |
| $48.68 | -0.60 | -1.2% | $49.01 | $49.41 | $48.11 | 966,500 | |
| $49.28 | +0.30 | +0.6% | $49.58 | $49.88 | $48.53 | 438,900 | |
| $48.98 | +1.49 | +3.1% | $47.50 | $49.20 | $46.99 | 421,100 | |
| $47.49 | -0.12 | -0.3% | $47.28 | $48.46 | $46.70 | 850,600 |
- Ticker
- Dusseldorf:A5I
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 17, 2026
AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference
Latest earnings call · Nov 3, 2026
AtriCure (NASDAQ:ATRC) Q3 2026 Earnings Call
Replay and transcript
Latest deck · July 2026
Q2 2026 Earnings Presentation
Earnings · 24 slides
Latest news
AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference
Nov 17, 2026
Closed $55.02 (-0.5%) on Nov 17, 2026
AtriCure Reports Third Quarter 2026 Financial Results
Nov 3, 2026
Closed $65.53 (+8.5%) on Nov 4, 2026
AtriCure to Participate at Upcoming Investor Conferences
Oct 26, 2026
Closed $61.08 (+3.6%) on Oct 26, 2026
AtriCure to Announce Third Quarter 2026 Financial Results
Oct 13, 2026
Closed $56.87 (-0.7%) on Oct 13, 2026
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
Aug 25, 2026
Closed $48.68 (-1.2%) on Aug 25, 2026
AtriCure Reports Second Quarter 2026 Financial Results
Jul 23, 2026
Closed $35.04 (+6.2%) on Jul 24, 2026
AtriCure to Announce Second Quarter 2026 Financial Results
Jul 2, 2026
Closed $31.79 (+6.9%) on Jul 2, 2026
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
May 27, 2026
Closed $27.45 (-4.7%) on May 27, 2026
AtriCure Reports First Quarter 2026 Financial Results
May 5, 2026
Closed $28.01 (-4.7%) on May 6, 2026
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
Apr 28, 2026
Closed $28.48 (-1.9%) on Apr 28, 2026
AtriCure, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 17 in the last 12 months · 142 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 31 calls with a replay · 31 with a transcript · latest Nov 3, 2026
- Decks
- 45 decks · latest July 2026
Where AtriCure, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ATRC · Home listing | NASDAQ | United States | USD |
| Frankfurt:A5I | Frankfurt | Germany | EUR |
| Tradegate:A5I | Tradegate | Germany | EUR |
| BOATS:ATRC | BOATS | United States | USD |
| Dusseldorf:A5I · This page | Dusseldorf | Germany | EUR |
| Hamburg:A5I | Hamburg | Germany | EUR |
Valuation
P/E 190× against a median of 25.4×: the highest of 9 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.69B USD
- P/E
- 190×
- EV/sales
- 4.6×
- EV/EBITDA
- 75.2×
- Price/book
- 5.3×
- Gross margin
- 76.7%
- Operating margin
- 2.9%
- Net margin
- 2.5%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.58
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AtriCure, Inc. · NASDAQ:ATRC | US$2.82B | US$2.69B | 190× | 4.6× | 75.2× | 5.3× | 2.5% | 0.1× | 0.58 |
| Zhende Medical Co., Ltd. Class A · SSE:603301 | US$3.23B | US$3.13B | 73.1× | 4.5× | n/a | 3.8× | 6.3% | 0.1× | n/a |
| Lepu Medical Technology (Beijing) Co., Ltd. Class A · SZSE:300003 | US$3.10B | US$3.03B | 31.4× | 3.3× | n/a | 1.3× | 10.7% | 0.2× | n/a |
| Carl Zeiss Meditec AG · XETR:AFX | US$3.06B | US$3.06B | 23.9× | 1.1× | n/a | 1.3× | 4.4% | 0.0× | n/a |
| Imricor Medical Systems, Inc. · ASX:IMR | US$2.99B | US$2.96B | n/a | 9,790× | n/a | 103× | n/a | 1.2× | n/a |
| TransMedics Group, Inc. · NASDAQ:TMDX | US$2.96B | US$2.52B | 20.5× | 3.5× | 19.8× | 5.4× | 19.9% | 0.1× | 1.31 |
| Ambu A/S Class B · OMXCOP:AMBU_B | US$2.92B | US$2.92B | 30.9× | 3.1× | 15.9× | 3.2× | 9.9% | 0.1× | n/a |
| Shanghai MicroPort MedBot (Group) Co., Ltd. Class H · HKEX:2252 | US$2.77B | US$2.74B | n/a | 33.1× | n/a | 44.9× | −45.3% | 1.0× | n/a |
| Ottobock SE & Co. KGaA · XETR:OBCK | US$2.65B | US$3.54B | 26.8× | 1.9× | 8.0× | 6.1× | 5.4% | 2.3× | n/a |
| Winner Medical Co. Ltd. Class A · SZSE:300888 | US$2.47B | US$1.75B | 21.2× | 1.0× | n/a | 1.4× | 6.9% | 0.0× | n/a |
| Medacta Group SA · SIX:MOVE | US$2.40B | US$2.72B | 22.8× | 3.6× | 13.0× | 4.5× | 14.0% | 0.7× | n/a |
| Median of the others | US$2.94B | US$2.94B | 25.4× | 3.4× | 14.5× | 4.1× | 6.9% | 0.2× | 1.31 |
Forecasts
4 strong buy · 3 buy · 3 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 64.89 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.43 · 7 analysts
- Revenue, year to Dec 2026
- 608.3M · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael H. Carrel | President, Chief Executive Officer and Director |
| Angela L. Wirick | Chief Financial Officer |
| Douglas J. Seith | Chief Operating Officer |
| Karl Dahlquist | Chief Legal Officer |
| Justin Noznesky | Chief Marketing and Strategy Officer |
| Salvatore Privitera | Chief Technical Officer |
| Vinayak Doraiswamy | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| B. Kristine Johnson | Director |
| Deborah H. Telman | Director |
| Karen N. Prange | Director |
| Maggie S. Yuen | Director |
| Michael H. Carrel | President, Chief Executive Officer and Director |
| Regina E. Groves | Director |
| Robert S. White | Director |
| Shlomi Nachman | Director |
| Sven A. Wehrwein | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| AtriCure (NASDAQ:ATRC) Q3 2026 Earnings Call | Tue, Nov 03, 2026 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q2 2026 Earnings Call | Thu, Jul 23, 2026 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q4 2025 Earnings Call | Tue, Feb 17, 2026 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q3 2025 Earnings Call | Wed, Oct 29, 2025 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q2 2025 Earnings Call | Tue, Jul 29, 2025 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q4 2024 Earnings Call | Wed, Feb 12, 2025 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q3 2024 Earnings Call | Tue, Oct 29, 2024 · 4:30 PM ET | Replay |
| AtriCure (NASDAQ:ATRC) Q2 2024 Earnings Call | Tue, Jul 30, 2024 · 4:30 PM ET | Replay |
All 31 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · After close | +8.5% |
| Q2 2026 | Jul 23, 2026 · After close | +6.2% |
| Q1 2026 | May 5, 2026 · After close | −4.7% |
| Q4 2025 | Feb 17, 2026 · After close | −2.1% |
| Q3 2025 | Oct 29, 2025 · After close | −3.8% |
| Q2 2025 | Jul 29, 2025 · After close | +10.7% |
| Q1 2025 | Apr 29, 2025 · After close | −13.7% |
| Q4 2024 | Feb 13, 2025 · Before open | −6.5% |
| Q3 2024 | Oct 29, 2024 · After close | +18.4% |
| Q2 2024 | Jul 30, 2024 · After close | −1.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 1, 2024 · After close | −10.3% |
| Q4 2023 | Feb 15, 2024 · After close | −4.4% |
| Q3 2023 | Nov 1, 2023 · After close | +4.5% |
| Q2 2023 | Jul 25, 2023 · After close | +8.5% |
| Q1 2023 | May 2, 2023 · After close | +10.0% |
| Q4 2022 | Feb 21, 2023 · After close | +8.3% |
| Q3 2022 | Nov 1, 2022 · After close | −6.0% |
| Q2 2022 | Aug 2, 2022 · After close | −0.6% |
| Q1 2022 | May 3, 2022 · After close | −2.4% |
| Q4 2021 | Feb 15, 2022 · After close | +3.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 24 slides | July 2026 |
| Investor Presentation (May 2026) | Investor deck | 25 slides | May 2026 |
| J.P. Morgan 44th Annual Healthcare Conference (January 2026) | Conference | 25 slides | January 2026 |
| Fact Sheet (December 2025) | Fact sheet | 2 slides | December 2025 |
| Q3 2025 Earnings Presentation | Earnings | 22 slides | October 2025 |
| Investor Presentation (August 2025) | Investor deck | 11 slides | August 2025 |
| Technical Presentation (August 2025) | Technical | 21 slides | August 2025 |
| Investor Presentation (July 2025) | Investor deck | 22 slides | July 2025 |
| Q1 2025 Earnings Presentation | Earnings | 22 slides | Apr 29, 2025 |
| Investor Day (March 2025) | Investor day | 30 slides | March 2025 |
All 45 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2024 Earnings Presentation | Earnings | 22 slides | Feb 12, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 21 slides | January 2025 |
| Q3 2024 Earnings Presentation | Earnings | 15 slides | Oct 29, 2024 |
| Fact Sheet (September 2024) | Fact sheet | 2 slides | September 2024 |
| Q2 2024 Earnings Presentation | Earnings | 15 slides | Jul 30, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 17 slides | May 1, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 28 slides | Nov 1, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 28 slides | Jul 25, 2023 |
| Investor Presentation (May 2023) | Investor deck | 28 slides | May 2023 |
| Investor Presentation (February 2023) | Investor deck | 28 slides | February 2023 |
| J.P. Morgan Healthcare Conference 2023 | Conference | 18 slides | Jan 9, 2023 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | November 2022 |
| Investor Presentation (September 2022) | Investor deck | 7 slides | September 2022 |
| Investor Presentation (August 2022) | Investor deck | 33 slides | August 2022 |
| Investor Presentation (May 2022) | Investor deck | 33 slides | May 2022 |
| Investor Presentation (January 2022) | Investor deck | 28 slides | Jan 10, 2022 |
| Fact Sheet (September 2021) | Fact sheet | 2 slides | September 2021 |
| Investor Presentation (August 2021) | Investor deck | 30 slides | Aug 4, 2021 |
| Investor Presentation (January 2021) | Investor deck | 26 slides | Jan 11, 2021 |
| Investor Presentation (2021) | Investor deck | 30 slides | 2021 |
| Investor Presentation (November 2020) | Investor deck | 23 slides | Nov 5, 2020 |
| Fact Sheet (September 2020) | Fact sheet | 2 slides | September 2020 |
| Investor Presentation (April 2020) | Investor deck | 25 slides | Apr 29, 2020 |
| Investor Presentation (January 2020) | Investor deck | 25 slides | Jan 13, 2020 |
| Merger or Acquisition (August 2019) | Merger or acquisition | 25 slides | Aug 12, 2019 |
| Investor Presentation (January 2019) | Investor deck | 41 slides | Jan 7, 2019 |
| Investor Presentation (January 2018) | Investor deck | 35 slides | Jan 8, 2018 |
| Investor Presentation (August 2017) | Investor deck | 36 slides | Aug 21, 2017 |
| Investor Presentation (January 2017) | Investor deck | 42 slides | Jan 9, 2017 |
| Investor Presentation (January 2016) | Investor deck | 37 slides | Jan 11, 2016 |
| Investor Presentation (January 2015) | Investor deck | 31 slides | Jan 12, 2015 |
| Investor Presentation (January 2013) | Investor deck | 22 slides | Jan 7, 2013 |
| Fact Sheet | Fact sheet | 2 slides | |
| Fact Sheet | Fact sheet | 2 slides | |
| Fact Sheet | Fact sheet | 2 slides |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 534.5M | 465.3M | 399.2M | 330.4M | 274.3M | 206.5M | 230.8M | 201.6M | 174.7M | 155.1M |
| Cost of revenue | 133.7M | 117.8M | 98.9M | 84.4M | 68.5M | 57.2M | 60.5M | 54.5M | 48.6M | 44.0M |
| Gross profit | 400.8M | 347.5M | 300.4M | 245.9M | 205.9M | 149.3M | 170.3M | 147.1M | 126.2M | 111.1M |
| Research and development | 99.2M | 96.2M | 73.9M | 57.3M | 48.5M | 43.1M | 41.2M | 34.7M | 34.1M | 35.8M |
| Selling, general and administrative | 311.0M | 291.4M | 253.1M | 231.3M | 204.6M | 150.8M | 167.1M | 129.5M | 117.0M | 106.4M |
| Operating income | -9.45M | -40.0M | -26.7M | -42.7M | 55.2M | -44.2M | -33.1M | -17.1M | -25.0M | -31.1M |
| Depreciation and amortization | 12.1M | 11.2M | 9.46M | 8.06M | 7.53M | 7.87M | 7.42M | 7.24M | 7.76M | 7.66M |
| EBITDA | 2.64M | -28.8M | -17.2M | -34.6M | 62.7M | -36.4M | -25.7M | -9.88M | -17.2M | -23.5M |
| Interest expense | 5.88M | 6.41M | 6.92M | 4.99M | 4.92M | 4.88M | 4.11M | 4.61M | 2.26M | 1.80M |
| Income before tax | -10.2M | -43.7M | -29.8M | -46.2M | 50.4M | -48.0M | -35.0M | -20.9M | -26.9M | -33.3M |
| Income tax | 1.28M | 1.02M | 591.0K | 268.0K | 188.0K | 114.0K | 199.0K | 226.0K | 14.0K | 40.0K |
| Net income | -11.4M | -44.7M | -30.4M | -46.5M | 50.2M | -48.2M | -35.2M | -21.1M | -26.9M | -33.3M |
| Earnings per share, basic | -0.24 | -0.95 | -0.66 | -1.02 | 1.11 | -1.14 | -0.94 | -0.62 | -0.83 | -1.05 |
| Earnings per share, diluted | -0.24 | -0.95 | -0.66 | -1.02 | 1.09 | -1.14 | -0.94 | -0.62 | -0.83 | -1.05 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 167.4M | 122.7M | 84.3M | 58.1M | 43.7M | 41.9M | 28.5M | 32.2M | 21.8M | 24.2M |
| Short-term investments | 0 | 53.0M | 63.0M | 75.4M | 202.3M | 53.3M | 92.2M | 12.6M | 19.8M | |
| Receivables | 66.7M | 60.3M | 52.5M | 42.7M | 33.0M | 23.1M | 28.0M | 25.2M | 23.1M | 21.1M |
| Inventory | 78.5M | 75.3M | 67.9M | 45.9M | 39.0M | 35.0M | 29.4M | 22.5M | 22.5M | 17.7M |
| Current assets | 322.5M | 267.8M | 266.2M | 215.2M | 196.1M | 306.7M | 143.2M | 174.7M | 82.3M | 85.7M |
| Property, plant and equipment | 42.6M | 31.4M | 28.3M | 32.6M | 27.1M | 28.7M | 30.0M | |||
| Goodwill | 234.8M | 234.8M | 234.8M | 234.8M | 234.8M | 234.8M | 234.8M | 105.3M | 105.3M | 105.3M |
| Total assets | 654.2M | 609.3M | 613.9M | 585.4M | 615.3M | 714.5M | 557.9M | 356.8M | 267.7M | 276.4M |
| Accounts payable | 25.3M | 25.0M | 27.4M | 19.9M | 18.6M | 12.7M | 14.9M | 9.66M | 12.4M | 10.7M |
| Current liabilities | 81.5M | 73.4M | 74.6M | 58.4M | 56.4M | 49.1M | 49.9M | 40.2M | 31.9M | 28.8M |
| Long-term debt | 61.9M | 61.9M | 60.6M | 56.8M | 59.7M | 53.4M | 59.6M | 35.6M | 24.1M | 23.9M |
| Total debt | 61.9M | 64.7M | 63.1M | 60.0M | 60.0M | 60.0M | 60.0M | 52.8M | 37.4M | 38.9M |
| Total liabilities | 162.2M | 148.4M | 147.8M | 128.7M | 131.6M | 302.1M | 310.5M | 107.4M | 106.5M | 108.0M |
| Shareholders' equity | 491.9M | 461.0M | 466.2M | 456.8M | 483.8M | 412.4M | 247.3M | 249.4M | 161.2M | 168.4M |
| Shares outstanding | 49.8M | 48.9M | 47.5M | 46.6M | 46.0M | 45.3M | 39.7M | 38.6M | 34.6M | 33.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 57.3M | 12.2M | 4.48M | -22.1M | -13.8M | -19.9M | -15.8M | -4.17M | -8.94M | -15.1M |
| Capital spending | -9.05M | -11.5M | -12.0M | -16.9M | -9.75M | -5.26M | -12.2M | -6.21M | -6.38M | -7.69M |
| Free cash flow | 48.3M | 745.0K | -7.51M | -39.0M | -23.5M | -25.1M | -28.0M | -10.4M | -15.3M | -22.8M |
| Cash from investing | -14.6M | 30.2M | 21.8M | 44.0M | 23.5M | -156.2M | -2.15M | -85.4M | 3.76M | -12.1M |
| Cash from financing | 1.18M | -3.60M | -32.0K | -7.06M | -7.64M | 189.4M | 14.4M | 100.2M | 2.76M | 27.7M |
| Dividends paid | 0 | 0 | -60.0K | -6.04M | -12.4M | -14.2M | -3.86M | -25.8M | -4.40M | -28.3M |
| Share buybacks | -11.2M | -6.95M | -6.56M | -12.2M | -18.0M | -13.0M | -9.03M | -4.46M | -2.01M | -1.70M |
| Change in cash | 44.7M | 38.4M | 26.2M | 14.4M | 1.71M | 13.5M | -3.75M | 10.4M | -2.40M | 444.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 24, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 28, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jul 27, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jul 27, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 27, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 23, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| SD · Specialized disclosure | May 27, 2026 | ESG report | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| 8-K · Current report | May 19, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K/A · Current report, amended | May 5, 2026 | Results | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 19, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 17, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Oct 29, 2025 | Results | SEC |
| 8-K · Current report | Oct 29, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 5, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jul 30, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 29, 2025 | ESG report | SEC |
| 144 · Notice of proposed sale | May 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 8-K · Current report | May 20, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 5, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Apr 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| S-3ASR · Registration statement | Feb 14, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 14, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2025 | Results | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 1, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| SD · Specialized disclosure | May 31, 2024 | ESG report | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 8-K · Current report | May 14, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 2, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | May 1, 2024 | Other filings | SEC |
| 8-K · Current report | May 1, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 3, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 3, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Mar 20, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from AtriCure, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 50,922,283
- Fully diluted
- 50,922,283
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 50,922,283 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 50,922,283 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sven A. Wehrwein Other companies: Proto Labs, Inc. (Director · Since at least Feb 23, 2012); Cogentix Medical Inc (Director · Mar 31, 2015 – Jul 31, 2015 · Past); SPS Commerce, Inc. (Director · Apr 21, 2010 – May 13, 2025 · Past); Compellent Technologies Inc (Director · Oct 9, 2007 – Feb 22, 2011 · Past); Synovis Life Technologies Inc (Director · Nov 1, 2006 – Oct 26, 2011 · Past); Autoscope Technologies Corporation (Director · Oct 1, 2006 – May 25, 2011 · Past); Uroplasty Inc (Director · Sep 1, 2006 – Mar 31, 2015 · Past); Vital Images Inc (Director · Mar 14, 2006 – Jun 15, 2011 · Past) | Director · Since at least Nov 11, 2016 |
| Karen N. Prange Other companies: Outset Medical, Inc. (Director · Since at least Jan 9, 2026); Embecta Corp. (Director · Since at least Apr 1, 2022); Nevro Corp (Director · Dec 17, 2019 – Apr 3, 2025 · Past); Cantel Medical Corp (Director · Oct 28, 2019 – Jun 2, 2021 · Past); Henry Schein, Inc. (EVP&CEO Gl.AH.Med.Den.Sur.Grp · May 17, 2016 – Mar 2, 2018 · Past) | Director · Since at least Dec 4, 2019 |
| B. Kristine Johnson Other companies: ClearPoint Neuro Inc. (Director · Since at least Sep 1, 2019); Paragon 28 Inc (Director · Dec 1, 2021 – Apr 21, 2025 · Past); The Spectranetics Corp (Director · May 31, 2012 – Aug 9, 2017 · Past); Piper Sandler Companies (Director · May 5, 2010 – Dec 13, 2019 · Past) | Director · Since at least Mar 21, 2017 |
| Scott William Drake Other companies: Paragon 28 Inc (Director · Oct 14, 2021 – May 18, 2022 · Past); Zayo Group Holdings Inc (Director · Nov 6, 2018 – Mar 9, 2020 · Past); The Spectranetics Corp (President, CEO, Director · Mar 5, 2012 – Aug 9, 2017 · Past) | Director · Sep 3, 2013 – May 7, 2021 · Past |
| Daniel P. Florin Other companies: Pulmonx Corporation (Board Member · Since at least Sep 30, 2020); Zimmer Biomet Holdings, Inc. (Exec. VP, CFO · Jun 29, 2015 – May 8, 2019 · Past) | Director · Dec 4, 2019 – May 20, 2021 · Past |
| Deborah H. Telman Other companies: Gilead Sciences, Inc. (EVP, Corporate Affairs & GC · Since at least Aug 1, 2022); Organon & Co. (EVP GC & Corporate Secretary · Jun 2, 2021 – May 4, 2022 · Past) | Director · Since at least Jun 15, 2021 |
| Thomas J Etergino Other companies: 1stdibs.com, Inc. (Chief Financial Officer · Since at least Mar 28, 2022); TheStreet Inc (Chief Financial Officer · Sep 7, 2010 – Sep 7, 2012 · Past) | Vice President and CFO · Jun 21, 2006 – Jun 21, 2006 · Past |
| Gene R McGrevin Other companies: Microtek Medical Holdings Inc (Director · May 1, 2006 – Nov 9, 2007 · Past) | Director · Apr 6, 2006 – Apr 6, 2006 · Past |
| Maggie S. Yuen Other companies: Penumbra, Inc. (Chief Financial Officer · Since at least Nov 4, 2026) | Director · Since at least Aug 7, 2026 |
| Maggie Yuen Other companies: Penumbra, Inc. (Chief Financial Officer · Since at least May 2, 2025) | Director · Since at least May 19, 2025 |
All 35 people
| Person | Seat |
|---|---|
| Mark A Collar Other companies: First Financial Bancorp. (Director · Feb 3, 2009 – May 23, 2016 · Past) | Director · Nov 6, 2008 – Mar 13, 2023 · Past |
| Michael H. Carrel Other companies: Inspire Medical Systems, Inc. (Director · Since at least Jul 20, 2026) | President, Chief Executive Officer and Director · Since at least Jun 30, 2025 |
| Patricia J Kennedy Other companies: Biotricity, Inc. (Director · Jul 16, 2019 – Apr 7, 2020 · Past) | VP and GM, International · Oct 1, 2011 – Oct 27, 2015 · Past |
| Regina E. Groves Other companies: Fulgent Genetics, Inc. (Director · Since at least Jan 3, 2023) | Director · Since at least Mar 21, 2017 |
| Stewart W Strong Other companies: Haemonetics Corporation (President, Global Hospital · Aug 6, 2021 – Jul 26, 2024 · Past) | VP Global Marketing · Dec 5, 2007 – Feb 9, 2012 · Past |
| Andrew L Lux | SVP, Ops & Quality · Jan 16, 2012 – Jun 30, 2017 · Past |
| Angela L. Wirick | Chief Financial Officer · Since at least Aug 6, 2020 |
| Deborah Lee Yount | Chief Human Resources Officer · Jun 1, 2022 – Mar 1, 2025 · Past |
| Deborah L Morley | VP Clinical Affairs · May 28, 2008 – Jul 29, 2009 · Past |
| Donald C Harrison | Director · May 15, 2012 – May 23, 2013 · Past |
| Douglas J. Seith | Chief Operating Officer · Since at least Jan 14, 2013 |
| Elizabeth D Krell | Director · Jun 21, 2006 – May 7, 2018 · Past |
| Elsa Chi Abruzzo | VP Regulatory&Clinical Affairs · Jun 20, 2007 – Jun 20, 2007 · Past |
| Julie A Piton | VP Fin & Admin & CFO · Jan 23, 2007 – Feb 17, 2012 · Past |
| Justin Noznesky | Chief Marketing and Strategy Officer · Since at least Feb 3, 2016 |
| Karl Dahlquist | Chief Legal Officer · Since at least May 20, 2021 |
| Lee R Wrubel | Director · Aug 5, 2005 – May 19, 2008 · Past |
| Mark R Lanning | Director · Mar 29, 2019 – May 5, 2021 · Past |
| Norman R Weldon | Director · Aug 5, 2005 – Aug 5, 2005 · Past |
| Robert S. White | Director · Since at least May 20, 2021 |
| Salvatore Privitera | Chief Technical Officer · Since at least Jun 14, 2010 |
| Shlomi Nachman | Director · Since at least Nov 5, 2026 |
| Shlomo Nachman | Director · Since at least Jan 4, 2024 |
| Tonya Austin | Chief Human Resources Officer · May 20, 2021 – May 13, 2022 · Past |
| Vinayak Doraiswamy | Chief Scientific Officer · Since at least May 28, 2025 |
Log in to ask 6ix AI your own questions about AtriCure, Inc.